Eintrag weiter verarbeiten
Ruxolitinib is effective in the treatment of a patient with refractory T-ALL
Gespeichert in:
Veröffentlicht in: | eJHaem 2(2021), 1, Seite 139-142 |
---|---|
Personen und Körperschaften: | , , , , , , , , , , , , |
Titel: | Ruxolitinib is effective in the treatment of a patient with refractory T-ALL/ Sonia Jaramillo, Hannah Hennemann, Peter Horak, Veronica Teleanu, Christoph E. Heilig, Barbara Hutter, Albrecht Stenzinger, Hanno Glimm, Benjamin Goeppert, Carsten Müller-Tidow, Stefan Fröhling, Stefan Schönland, Richard F. Schlenk |
Format: | E-Book-Kapitel |
Sprache: | Englisch |
veröffentlicht: |
2021
|
Gesamtaufnahme: |
: eJHaem, 2(2021), 1, Seite 139-142
, volume:2 |
Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
Zusammenfassung: | T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic blood cell transplantation of a refractory T-ALL with a Janus kinase 3 (JAK3) mutation. In this case report, we were able to show the potential benefit of the JAK inhibitor ruxolitinib in JAK3-mutated refractory T-ALL and emphasize the importance of integrating molecular markers in current treatment decision making for patients with T-ALL. |
---|---|
Beschreibung: |
First published: 04 December 2020 Gesehen am 07.09.2021 |
Umfang: | 4 |
ISSN: |
2688-6146
|
DOI: | 10.1002/jha2.143 |